University of Notre Dame DU Lac cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,588 shares of the biotechnology company’s stock after selling 475 shares during the period. University of Notre Dame DU Lac’s holdings in United Therapeutics were worth $2,296,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of UTHR. Quantbot Technologies LP lifted its holdings in United Therapeutics by 537.3% during the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 822 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new position in United Therapeutics during the third quarter worth about $156,000. Eagle Global Advisors LLC bought a new position in United Therapeutics during the second quarter worth about $206,000. Toronto Dominion Bank lifted its holdings in United Therapeutics by 244.7% during the third quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 1,351 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new position in United Therapeutics during the third quarter worth about $233,000. Hedge funds and other institutional investors own 99.94% of the company’s stock.
Several research analysts have weighed in on the company. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. TheStreet lowered United Therapeutics from a “b-” rating to a “c” rating in a report on Friday, September 29th. Zacks Investment Research upgraded United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, Oppenheimer restated a “buy” rating on shares of United Therapeutics in a report on Friday, September 8th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $136.10.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The business had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same quarter in the prior year, the company posted $4.23 earnings per share. United Therapeutics’s revenue was up 9.1% on a year-over-year basis. equities analysts expect that United Therapeutics Corporation will post 12.45 earnings per share for the current fiscal year.
In related news, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the sale, the chief executive officer now owns 2,301 shares in the company, valued at $306,769.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,241 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $128.95, for a total value of $160,026.95. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $2,919,517 in the last quarter. 7.80% of the stock is currently owned by corporate insiders.
United Therapeutics Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.